Mar 26 |
Cerus Corporation Announces FDA Approval of Extended Shelf Life for INTERCEPT Platelet Processing Sets – Doubling Previous Shelf Life
|
Mar 19 |
Why Blood Components-Focused Cerus Stock Is Rising Tuesday
|
Mar 19 |
Cerus' soars on meeting main goal of late stage trial for INTERCEPT RBCs in heart surgery patients
|
Mar 19 |
Cerus Corporation Announces Positive Topline Results for the Phase 3 Clinical Trial of the INTERCEPT Blood System for Red Blood Cells in Cardiovascular Surgery Patients
|
Mar 15 |
Insider Sell: President and CEO William Greenman Sells 125,926 Shares of Cerus Corp (CERS)
|
Mar 15 |
Insider Sell: COO Vivek Jayaraman Sells 53,041 Shares of Cerus Corp (CERS)
|
Mar 8 |
Earnings Release: Here's Why Analysts Cut Their Cerus Corporation (NASDAQ:CERS) Price Target To US$4.13
|
Mar 7 |
Cerus Corp (CERS) Posts Narrowed Q4 Net Loss and Achieves Adjusted EBITDA Breakeven
|
Mar 7 |
Cerus Corporation (NASDAQ:CERS) Q4 2023 Earnings Call Transcript
|
Mar 7 |
Cerus Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag
|